These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 7667193)

  • 1. Soft drugs. 19. Pharmacokinetics, metabolism and excretion of a novel soft corticosteroid, loteprednol etabonate, in rats.
    Bodor N; Wu WM; Murakami T; Engel S
    Pharm Res; 1995 Jun; 12(6):875-9. PubMed ID: 7667193
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetics and delta1-cortienic acid excretion after intravenous administration of prednisolone and loteprednol etabonate in rats.
    Wu WM; Tang Y; Buchwald P; Bodor N
    Pharmazie; 2010 Jun; 65(6):412-6. PubMed ID: 20614688
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics of the sequential metabolites of loteprednol etabonate in rats.
    Wu WM; Huang F; Lee Y; Buchwald P; Bodor N
    J Pharm Pharmacol; 2008 Mar; 60(3):291-7. PubMed ID: 18284808
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Soft drugs. 18. Oral and rectal delivery of loteprednol etabonate, a novel soft corticosteroid, in rats--for safer treatment of gastrointestinal inflammation.
    Bodor N; Murakami T; Wu WM
    Pharm Res; 1995 Jun; 12(6):869-74. PubMed ID: 7667192
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetic characterization and tissue distribution of the new glucocorticoid soft drug loteprednol etabonate in rats and dogs.
    Hochhaus G; Chen LS; Ratka A; Druzgala P; Howes J; Bodor N; Derendorf H
    J Pharm Sci; 1992 Dec; 81(12):1210-5. PubMed ID: 1491342
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Metabolism, distribution, and transdermal permeation of a soft corticosteroid, loteprednol etabonate.
    Bodor N; Loftsson T; Wu WM
    Pharm Res; 1992 Oct; 9(10):1275-8. PubMed ID: 1448425
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ocular absorption and distribution of loteprednol etabonate, a soft steroid, in rabbit eyes.
    Druzgala P; Wu WM; Bodor N
    Curr Eye Res; 1991 Oct; 10(10):933-7. PubMed ID: 1959381
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The effects of delta1-cortienic acid on skin blanching, pharmacokinetics and stability of loteprednol etabonate.
    Wu WM; Bodor ET; Howes J; Bodor N
    Pharmazie; 2012 May; 67(5):406-10. PubMed ID: 22764572
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prolonged exposure to loteprednol etabonate in human tear fluid and rabbit ocular tissues following topical ocular administration of Lotemax gel, 0.5%.
    Glogowski S; Lowe E; Siou-Mermet R; Ong T; Richardson M
    J Ocul Pharmacol Ther; 2014 Feb; 30(1):66-73. PubMed ID: 24325539
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The conjunctival provocation test model of ocular allergy: utility for assessment of an ocular corticosteroid, loteprednol etabonate.
    Abelson M; Howes J; George M
    J Ocul Pharmacol Ther; 1998 Dec; 14(6):533-42. PubMed ID: 9867336
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comments concerning "Pharmacokinetic characterization and tissue distribution of the new glucocorticoid soft drug loteprednol etabonate in rats and dogs".
    Sloan KB; Perrin JH
    J Pharm Sci; 1994 Jul; 83(7):1066-8. PubMed ID: 7965668
    [No Abstract]   [Full Text] [Related]  

  • 12. A double-masked, placebo-controlled evaluation of 0.5% loteprednol etabonate in the treatment of postoperative inflammation. The Loteprednol Etabonate Postoperative Inflammation Study Group 2.
    Ophthalmology; 1998 Sep; 105(9):1780-6. PubMed ID: 9754192
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Failure to detect systemic levels, and effects of loteprednol etabonate and its metabolite, PJ-91, following chronic ocular administration.
    Howes J; Novack GD
    J Ocul Pharmacol Ther; 1998 Apr; 14(2):153-8. PubMed ID: 9572541
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identification of esterase involved in the metabolism of two corticosteroid soft drugs.
    Samir A; Bodor N; Imai T
    Biochem Pharmacol; 2017 Mar; 127():82-89. PubMed ID: 28017774
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ocular Pharmacokinetics of a Novel Loteprednol Etabonate 0.4% Ophthalmic Formulation.
    Schopf L; Enlow E; Popov A; Bourassa J; Chen H
    Ophthalmol Ther; 2014 Dec; 3(1-2):63-72. PubMed ID: 25134493
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Loteprednol etabonate ophthalmic suspension 0.5 %: efficacy and safety for postoperative anti-inflammatory use.
    Amon M; Busin M
    Int Ophthalmol; 2012 Oct; 32(5):507-17. PubMed ID: 22707339
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Soft drugs--10. Blanching activity and receptor binding affinity of a new type of glucocorticoid: loteprednol etabonate.
    Druzgala P; Hochhaus G; Bodor N
    J Steroid Biochem Mol Biol; 1991 Feb; 38(2):149-54. PubMed ID: 2004037
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intranasal loteprednol etabonate in healthy male subjects: pharmacokinetics and effects on endogenous cortisol.
    Hermann R; Locher M; Siebert-Weigel M; LaVallee N; Derendorf H; Hochhaus G
    J Clin Pharmacol; 2004 May; 44(5):510-9. PubMed ID: 15102872
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A comparison of intraocular pressure elevating activity of loteprednol etabonate and dexamethasone in rabbits.
    Bodor N; Bodor N; Wu WM
    Curr Eye Res; 1992 Jun; 11(6):525-30. PubMed ID: 1505197
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Potential Use of Cyclodextrin Complexes for Enhanced Stability, Anti-inflammatory Efficacy, and Ocular Bioavailability of Loteprednol Etabonate.
    Soliman OAE; Mohamed EAM; El-Dahan MS; Khatera NAA
    AAPS PharmSciTech; 2017 May; 18(4):1228-1241. PubMed ID: 27469220
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.